Cannasouth Limited (NZX:CBD) has received clarification during recent discussions with the Medicinal Cannabis Agency related to technical aspects associated with achieving the New Zealand Minimum Quality Standard for cannabis flower as a finished product. The insights gained have helped Cannasouth optimise post-harvest processes which will ultimately lead to a higher quality finished product.
The adopted process improvements remove complexity and streamline our operations, however require additional data to validate the changes. This data will be gathered during our upcoming commercial harvest scheduled to commence on the 19th of September.
Validation is a key component of the Good Manufacturing Practices (GMP) accreditation process. Cannasouth has sought deferral of its GMP audit while the new data pack is assembled. Cannasouth is working with the regulators to arrange a new audit date at the earliest opportunity.
GMP covers the post-harvest, drying and packing processes and is required for higher value premium flower to be used as a finished product in most jurisdictions, including New Zealand. This is an important distinction from Good Agricultural Collection Practices (GACP) accreditation, which Cannasouth achieved in August 2022, which opens the pathway for the export of cannabis flower as a start material for further manufacture.
-ENDS-
For further information visit www.cannasouth.co.nz or contact:
Mark Lucas
CEO / Executive Director
Email: [email protected]
Mobile: 021 484 649
Colin Foster
CFO / Company Secretary
Email: [email protected]
Mobile: 027 577 1498
CEOs may not like it, but the returns are undeniable.
Banks’ credit ratings likely unmoved if Additional Tier 1 capital phased out.
The S&P/NZX 50 gained 0.2% to 13,234.89 points on Tuesday.
To join your company account for BusinessDesk and enjoy full access, enter your email and we’ll send you details